• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success

    Abbott Invests €440 in New Irish Facility

    FDA Approves Guardant Health's NGS-Based Companion Diagnostic

    Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

    NanoVibronix Strengthening its Supply Chain to Address Potential Delays
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Parylene Coatings for Medical Device Technologies

    The Big Shift: Nearshoring Trends in Medtech Manufacturing

    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Cooling and Melting the Pain Away

    What Are the Fundamentals of Go-To-Market Strategy in Medical Devices?

    Minding the Gap: How Harmonizing Quality Systems Pays Off

    Building Strong Partnerships Between Medtech and Surgeon-Learning Platforms

    Four Key Considerations for OEMs Transferring a Product Program
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Xact Wire EDM Corp.

    Cirtec Medical

    JBC Technologies
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Medical Computing: COM Express Processes Real-Time Data at the Edge

    The Importance of Building Successful Supplier Relationships

    The Benefits of Outsourcing Innovation in Medtech Manufacturing

    Patching Healthcare Cybersecurity Risks in the Internet of Medical Things

    Leveraging Open Healthcare Data Standards to Improve Medical Device Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Trademark Plastics Inc.

    Arthur G. Russell Co. Inc., The

    Xact Wire EDM Corp.

    Cirtec Medical

    JBC Technologies
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    COVID-19 Test Makers Confirm Their Assays Spot Omicron Variant

    Over 30 mutations to the virus' spike protein raise concerns about diagnostic testing accuracy and efficacy.

    COVID-19 Test Makers Confirm Their Assays Spot Omicron Variant
    Sam Brusco, Associate Editor12.01.21
    Initially identified in South Africa and subsequently in a number of African, European, and North American countries, the Omicron variant (B.1.1.529) of the SARS-CoV-2 virus contains about 30 mutations in its spike protein alone. As a result, there has been some concern that currently available diagnostic tests may be less effective in spotting the Omicron variant.
     
    The WHO reported preliminary evidence suggests Omicron has an increased transmission risk compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on existing vaccine and test accuracy.
     
    Firms specializing in diagnostic tests for COVID-19 are working quickly to confirm their tests are still effective. Following are those that have confirmed via internal studies. (This list will be updated as more results come to light.)
     

    Abbott Laboratories

     
    The company conducted an assessment of Omicron and confirmed its rapid and PCR COVID-19 tests can detect the virus. According to Abbott, although the spike protein is mutated, the tests do not rely on the spike gene to spot the virus. Abbott’s Pandemic Defense Coalition— network of research, academic, and public health collaborators strategically placed around the globe—is actively sequencing viruses to look for COVID variants. The group is actively engaged with its partner in South Africa on Omicron.
     
    “We also have an entire team of Abbott scientists dedicated to monitoring COVID-19 variants,” the company announced on its website. “To date, we have carefully analyzed over 1.4 million sequences from 63 different variants and none have impacted the ability of our diagnostic tests to detect the virus. And as soon as the Omicron sequence was made available, our scientists worked non-stop to evaluate it and determined the mutations would not impact the ability of our rapid and PCR tests to detect it."
     

    Becton Dickinson

     
    The company released a statement on Tuesday regarding testing for the Omicron variant. Dave Hickey, BD’s president of Life Sciences, told the press:
     
    "Our analysis of the Omicron variant was conducted using all available genome sequences deposited in the GISAID EpiCoV database as of Nov. 29. When live viral samples are made available, BD will perform additional rigorous testing in the laboratory. BD actively monitors all sequenced SARS-CoV-2 isolates worldwide. Our team has evaluated over 3.5 million genomes to monitor for emerging variants. Variants of concern have been tested by BD and our partners and no undetectable variants have been identified. "Reliable and widely available testing remains one of the most important measures to mitigate the spread of COVID-19. BD will continue to monitor and verify the performance of its COVID-19 tests to serve its mission of advancing the world of health."

    BioGX


    According to the company, its portfolio of BioGX SARS-CoV-2 products that target the nucleocapsid (N-gene) and envelope (E-gene) will spot Omicron. Analysis conducted by BioGX confirmed the BioGX portfolio of COVID-19 tests maintain detection coverage for all variants of interest and variants of concern.

    Hologic

     
    Hologic’s three SARS-CoV-2 tests—the Aptima SARS-CoV-2 Assay, Aptima SARS-CoV-2/Flu Assay, and Panther Fusion SARS-CoV-2 Assay—all detect the recently emerged variant, according to the company. Hologic analyzed genetic sequences from over 175 Omicron-infected samples to determine that none of the new mutations occur in the genome regions these tests target.
     
    “We fully expect that SARS-CoV-2 will continue to evolve, as that is the natural path for viruses,” Kevin Thornal, Hologic’s Diagnostic Solutions Division president told the press. “We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays.”
     

    Lucira

     
    The company’s Lucira Check-It (OTC) and All-In-One (Rx) test kits have been confirmed by the company to detect Omicron. The company’s evaluation determined its COVID-19 assay can spot 100 percent of genome sequences of the Omicron variant available in the GISAID database as of November 26.
     
    "While there is still a lot to learn about the Omicron variant, the ability to detect circulating strains is fundamental to help slow the virus spread," Debkishore Mitra, Ph.D., chief technology officer and co-founder of Lucira Health told the press. "This is why our team is relentlessly assessing newly available genetic sequences against our test."
     

    PerkinElmer

     
    The company has reported its SARS-CoV RT-PCR tests are not impacted by Omicron’s emergence. The over 30 mutations occur in its S gene, and the company’s assays don’t target the S gene for SARS-CoV-2 detection. In silico assessment against variant databases such as GISAID confirm that none of the mutations associated with Omicron variant impact PerkinElmer’s PCR based diagnostic kits.
     
    “Omicron contains a large number of mutations in the S gene, adding to concerns about transmissibility, immune system evasion, and vaccine resistance. It is critical to ensure that the diagnostic accuracy of SARS-CoV-2 detection assays is not compromised due to Omicron and other variants,” Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer told the press.
     

    QIAGEN

     
    The company’s PCR tests remain accurate and effective, according to an announcement made on November 26. This includes the artus SARS-CoV-2 Prep&Amp UM Kit, QIAstat-Dx syndromic testing system, NeuMoDx 96 and 288 integrated PCR testing systems, QIAcuity digital PCR solution, and QIAprep& Viral RNA kit.
     
    The assessment was made against data available in the GISAID and GenBank public databases.
     
    “We are pleased to report that the emergence of this new variant of concerns, as has been the case with other variants, has had no impact on the effectiveness of our SARS-CoV-2 PCR tests,” QIAGEN chief medical officer Dr. Davide Manissero told the press. “Further genomic sequencing of SARS-CoV-2 samples worldwide will vastly increase transparency and help us identify and respond to potentially dangerous mutations of the virus, while at the same time broadening the database we can use to verify if vaccines and tests continue to be effective.”
     

    Rheonix

     
    The company announced its Rheonix COVID-19 MDx assay will detect the newly emerging variant. Assessments indicated the assay spots all SARS-CoV-2 variants of concern.
     
    “Rheonix continually assesses the potential impact of variants on assay performance by conducting in silico analysis of publicly available SARS-CoV-2 sequence data as well as laboratory testing of prevalent variants,” Gwendolyn Spizz, Ph.D., chief scientist at Rheonix told the press. “The robust design of the Rheonix COVID-19 MDx Assay has allowed for the detection of all designated variants of concern to date, including the delta variant. Based on our analysis, we are highly confident in our ability to detect the omicron variant, and we will continue to rigorously monitor the public genome databases.”

    Seegene


    The company's Allplex SARS-CoV-2 Master Assay was deemed capable of detecting Omicron's unique pattern of mutations. The test simultaneously detects four wild-type SARS-CoV-2 genes (E gene, RdRP gene, N gene, and S gene) and five notable S-gene mutations: HV69/70 deletion, Y144 deletion, E484K, N501Y, and P681H. Since the latest variant Omicron contains HV69/70 deletion, N501Y, and P681H mutations, this test can detect Omicron.

    “In order to contain the further spread of Omicron, it is extremely important to preemptively detect the Omicron variant at the primary screening stage,” Dr. Jong-Yoon Chun, Seegene founder and CEO told the press. “To that end, we will fully support countries in need of our tests to enable more rapid detection of the latest variant. Along with strengthening surveillance testing, the implementation of relevant quarantine measures will give more time for countries around the world to contain the rising Omicron infections and protect their citizens.”
     

    Thermo Fisher Scientific

     
    The company’s TaqPath COVID-19 Combo Kit and TaqPath COVID-19 CE-IVD RT-PCR Kit accuracy has not been impacted. According to the company, The TaqPath COVID-19 assays detect infections by identifying the presence of three gene targets from the orf1a/b, S, and N regions of the virus. By surveying across multiple genes, the test can report accurate results even when one of the targets is impacted by a mutation.
     
    In addition to the original tests, the firm has developed the TaqPath COVID-19 2.0 tests to compensate for emerging mutations. The assays detect SARS-CoV-2 by utilizing eight gene targets across the orf1a/b and N regions of the virus. These were also assessed against sequences in the GISAID public database and confirmed in silico to detect all B.1.1.529 mutations with no loss in sensitivity.
     
    Specific genotyping assays to detect Omicron are being developed for the company’s TaqMan Mutation Panel. It is currently used for research purposes and already has a menu of over 50 assays to assess confirmed COVID-19 cases for the presence of known variants and mutations.
     
    "Like all viruses, we have always known that SARS-CoV-2 would continue to mutate, and that effective testing strategies are a key to curbing the pandemic," said Mark Stevenson, exec. VP and COO of Thermo Fisher Scientific. "That is why we developed assays with additional built-in checks and balances, to ensure that clinicians, researchers and public health officials would have effective tools to accurately test for COVID-19 even as the genetic makeup of the virus evolved."

    Tests Expected to Fail

    Due to the inability of these tests to detect the Omicron variant, the FDA recommends the following tests should not be used until the issue is resolved:

    • Meridian Bioscience, Inc. Revogene SARS-CoV-2
    • Tide Laboratories DTPM COVID-19 RT-PCR Test
    • Applied DNA Science Linea COVID-19 Assay Kit
    Related Searches
    • Diagnostics
    Related Knowledge Center
    • Diagnostics
    Loading, Please Wait..

    Trending
    • Cardinal Health CEO Mike Kaufmann Steps Down
    • BD Recalls Intraosseous Products Over Multiple Issues
    • Abbott Invests €440 In New Irish Facility
    • Medidata Unveils New Tech To Improve Clinical Trial Oversight
    • Chronic, Infectious Disease Prevalence To Benefit Vital Signs Monitoring Market
    Breaking News
    • 'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    • Abbott Invests €440 in New Irish Facility
    • FDA Approves Guardant Health's NGS-Based Companion Diagnostic
    • Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment
    • NanoVibronix Strengthening its Supply Chain to Address Potential Delays
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Parylene Coatings for Medical Device Technologies
    • Nearshoring Trends in Medtech Manufacturing
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Paul N. Gardner Now Offers Bacharach Sling Psychrometer
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    FDA Approves Guardant Health's NGS-Based Companion Diagnostic
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    J&J To Stop Global Sales of Talc-Based Products by 2023
    Net Sales Increase 2% for Naples Soap Company in Second Quarter
    Net Revenue Down 12% for Grove Collaborative in Second Quarter
    Ink World

    Latest Breaking News From Ink World

    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Paul N. Gardner Offers Bacharach Sling Psychrometer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Freudenberg to Present Friction Inserts for Wind Energy
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Bone Growth Stimulators Market to Top $3B by 2030
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi
    Identiv Delivers Impressive 41% Year-over-Year Growth in RFID Business

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login